[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Abemaciclib",
            "Result": [
                "Score: -2 \u2013 Reasoning: \n\nAll abstracts consistently report that treatment with Abemaciclib leads to improved clinical outcomes (particularly progression-free survival and objective response rates), which directly contradicts the hypothesis that Abemaciclib worsens breast cancer patient outcomes. Below is the step-by-step reasoning with supporting evidence from the cited PMIDs:\n\n1. Multiple Phase III Trials Demonstrate Improved Progression-Free Survival (PFS):  \n   \u2022 PMID: 580237 \u2013 The median PFS for the Abemaciclib-treated group was 16.4 months versus 9.2 months for the control arm.  \n   \u2022 PMID: 632330 \u2013 Again, median PFS was significantly longer (16.4 vs. 9.2 months) for the Abemaciclib arm.  \n   \u2022 PMID: 433862 \u2013 Reported a median PFS of 28.6 months with Abemaciclib vs. 14.7 months in the control.  \n   \u2022 PMID: 889006 \u2013 Showed a statistically significant improvement in PFS (16.4 vs. 9.3 months) for Abemaciclib.  \n   \u2022 PMID: 213266 \u2013 Noted a prolonged PFS of 16.4 vs. 9.2 months with Abemaciclib treatment.  \n\n   These findings all indicate that Abemaciclib delays disease progression compared to placebo or standard endocrine therapy alone, thus improving rather than worsening outcomes.\n\n2. Increased Objective Response Rate (ORR) Supports Better Efficacy:  \n   \u2022 PMID: 580237 \u2013 Reported an ORR of 35.6% in the Abemaciclib arm versus 18.9% with placebo.  \n   \u2022 PMID: 632330 \u2013 Demonstrated an ORR of 35.6% with Abemaciclib vs. 18.9% in control.  \n   \u2022 PMID: 433862 \u2013 Observed an ORR of 48.3% in the Abemaciclib group versus 21.4% for the comparator.  \n   \u2022 PMID: 889006 \u2013 Found an ORR of 48.1% with Abemaciclib, significantly outperforming the 21.3% in the placebo arm.  \n   \u2022 PMID: 213266 \u2013 ORR was 35.1% for Abemaciclib vs. 16.7% for placebo.  \n\n   In each study, more patients treated with Abemaciclib showed tumor shrinkage or stable disease compared to control, ruling out any consistent suggestion that Abemaciclib might worsen outcomes.\n\n3. Safety Profile Is Manageable and Does Not Undermine Clinical Benefit:  \n   \u2022 Across the abstracts (e.g., PMID: 580237, 632330, 889006, 213266), adverse events such as neutropenia and diarrhea, while more common in the Abemaciclib arms, were typically manageable with supportive care and dose modifications.  \n\n   These effects, though noted, do not override the overall clinical benefit, especially in light of significantly prolonged PFS and improved ORR.\n\nConclusion:  \nBecause every study consistently shows improved rather than worsened patient outcomes (extended progression-free survival, higher objective response rates, and manageable toxicity), the hypothesis that Abemaciclib would worsen breast cancer patient outcomes is strongly refuted by the evidence.  \n\nScore: -2 \u2013 The data uniformly contradict the proposed worsening effect of Abemaciclib, indicating a clear refutation of the hypothesis."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 580237. **Title:** Efficacy and Safety of Abemaciclib in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Phase III Randomized Controlled Trial  \n\n**Background:** Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have revolutionized the treatment of hormone receptor-positive (HR+), HER2-negative advanced breast cancer. Abemaciclib, a selective CDK4/6 inhibitor, has shown promise in preclinical and early-phase clinical trials. This phase III study evaluated the efficacy and safety of abemaciclib in combination with endocrine therapy versus endocrine therapy alone in patients with HR+, HER2-negative advanced breast cancer.  \n\n**Methods:** In this multicenter, randomized, double-blind, placebo-controlled trial, 672 patients with HR+, HER2-negative advanced breast cancer were enrolled. Participants were randomized 1:1 to receive either abemaciclib (150 mg twice daily) plus fulvestrant (500 mg intramuscularly every 28 days) or placebo plus fulvestrant. The primary endpoint was progression-free survival (PFS) assessed by RECIST v1.1. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Statistical analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models.  \n\n**Results:** After a median follow-up of 28.5 months, the abemaciclib group demonstrated a statistically significant improvement in PFS compared to the placebo group (median PFS: 16.4 vs. 9.2 months; hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.45\u20130.68; p < 0.001). The ORR was significantly higher in the abemaciclib arm (35.6% vs. 18.9%, p < 0.001). Interim OS analysis showed a trend toward benefit (HR 0.79, 95% CI 0.62\u20131.01; p = 0.06). The most common grade 3/4 adverse events in the abemaciclib group were neutropenia (24.3%) and diarrhea (12.1%), which were manageable with dose adjustments.  \n\n**Conclusion:** Abemaciclib significantly improves PFS and ORR in patients with HR+, HER2-negative advanced breast cancer, with a tolerable safety profile. These findings support the use of abemaciclib as a standard-of-care treatment in this population. Further follow-up is warranted to confirm OS benefits.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX  \n\n**Keywords:** Abemaciclib, CDK4/6 inhibitor, hormone receptor-positive breast cancer, HER2-negative, progression-free survival\n\n---\n\nPMID: 632330. **Title:** Efficacy and Safety of Abemaciclib in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Randomized Phase III Trial  \n\n**Background:** Abemaciclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has shown promise in improving outcomes for patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer. This study evaluated its efficacy and safety compared to standard endocrine therapy alone.  \n\n**Population:** A total of 672 postmenopausal women with HR+, HER2-negative advanced breast cancer who had progressed on prior endocrine therapy were enrolled. Participants were randomized 1:1 to either the intervention or control arm.  \n\n**Intervention:** Patients in the intervention arm received abemaciclib (150 mg twice daily) plus fulvestrant (500 mg intramuscularly on days 1, 15, and 29, then every 28 days).  \n\n**Comparison:** The control arm received fulvestrant plus placebo.  \n\n**Outcomes:** The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. At a median follow-up of 24.5 months, the abemaciclib group demonstrated significantly longer median PFS (16.4 months vs. 9.2 months in the control arm; hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.45\u20130.68; p < 0.001). The ORR was 35.6% in the abemaciclib group versus 18.9% in the control group (p < 0.001). Interim OS analysis showed a trend toward improvement (HR 0.78, 95% CI 0.60\u20131.02; p = 0.06). The most common grade 3/4 adverse events in the abemaciclib arm were neutropenia (24.1%) and diarrhea (9.8%), which were manageable with dose adjustments.  \n\n**Conclusion:** Abemaciclib combined with fulvestrant significantly improved PFS and ORR in patients with HR+, HER2-negative advanced breast cancer, supporting its use as a standard therapy in this population. Further follow-up is needed to confirm OS benefits.  \n\n**Keywords:** Abemaciclib, CDK4/6 inhibitor, hormone receptor-positive breast cancer, progression-free survival, randomized controlled trial.\n\n---\n\nPMID: 433862. **Abstract**  \nAbemaciclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has emerged as a promising therapeutic agent for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. This multicenter, randomized, phase III clinical trial evaluated the efficacy and safety of abemaciclib in combination with endocrine therapy compared to endocrine therapy alone in 672 patients with metastatic breast cancer. Progression-free survival (PFS) was the primary endpoint, with secondary endpoints including overall survival (OS), objective response rate (ORR), and safety profile. After a median follow-up of 28.5 months, the abemaciclib combination group demonstrated a statistically significant improvement in median PFS (28.6 months vs. 14.7 months; hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.42\u20130.67; p < 0.001) compared to the control arm. The OS data, though immature, showed a favorable trend (HR 0.79, 95% CI 0.61\u20131.02; p = 0.067). The ORR was significantly higher in the abemaciclib group (48.3% vs. 21.4%; p < 0.001), with a median duration of response of 24.9 months versus 12.5 months (p < 0.001). The most common adverse events in the abemaciclib arm were diarrhea (83.2%), neutropenia (41.5%), and fatigue (35.7%), though these were predominantly grade 1\u20132 and manageable with dose adjustments. Subgroup analyses confirmed consistent PFS benefits across all predefined subgroups, including prior endocrine therapy exposure and visceral metastasis status. These findings underscore abemaciclib as a transformative treatment option, significantly prolonging PFS and enhancing clinical outcomes in HR+/HER2- advanced breast cancer. Further follow-up is warranted to assess long-term survival benefits and optimize therapeutic sequencing in this patient population.\n\n---\n\nPMID: 889006. Abemaciclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has emerged as a promising therapeutic agent for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. This phase III, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of abemaciclib in combination with endocrine therapy (ET) in 669 patients with HR+/HER2- metastatic breast cancer who had progressed on prior ET. Patients were randomized 2:1 to receive abemaciclib (150 mg twice daily) plus ET (fulvestrant or an aromatase inhibitor) or placebo plus ET. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and safety. After a median follow-up of 22.3 months, the abemaciclib arm demonstrated a statistically significant improvement in median PFS compared to the placebo arm (16.4 vs. 9.3 months; hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.45\u20130.68; p < 0.001). OS data, though immature, showed a trend toward benefit (HR 0.76, 95% CI 0.57\u20131.02; p = 0.06). The ORR was significantly higher in the abemaciclib group (48.1% vs. 21.3%; p < 0.001), with a median duration of response of 25.6 months (95% CI 20.4\u201330.2) versus 12.9 months (95% CI 9.1\u201316.7) in the placebo group. The most common adverse events (AEs) in the abemaciclib arm were diarrhea (82.3%), neutropenia (45.7%), and fatigue (39.1%), though grade 3/4 AEs were manageable with dose adjustments. These findings underscore abemaciclib\u2019s significant clinical benefit in improving PFS and ORR in HR+/HER2- advanced breast cancer, reinforcing its role as a standard-of-care treatment in this patient population. Further follow-up is warranted to confirm OS benefits and long-term safety.\n\n---\n\nPMID: 213266. **Title:** Efficacy and Safety of Abemaciclib in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Phase III Randomized Controlled Trial  \n\n**Background:** Abemaciclib, a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has emerged as a promising therapeutic option for advanced breast cancer. This study evaluated its efficacy and safety in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer patients.  \n\n**Population:** A total of 672 postmenopausal women with HR+, HER2- advanced breast cancer who had progressed on prior endocrine therapy were enrolled. Participants were randomized 1:1 to receive either abemaciclib plus fulvestrant (n=336) or placebo plus fulvestrant (n=336).  \n\n**Intervention:** The experimental arm received abemaciclib (150 mg orally twice daily) combined with fulvestrant (500 mg intramuscularly on days 1, 15, and 29, then every 4 weeks). The control arm received placebo plus fulvestrant on the same schedule.  \n\n**Comparison:** Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were compared between the two arms. Safety profiles were also assessed.  \n\n**Outcomes:** The median PFS was significantly longer in the abemaciclib group (16.4 months [95% CI: 14.2\u201318.6]) compared to the placebo group (9.2 months [95% CI: 7.4\u201311.1]; hazard ratio [HR]=0.55, 95% CI: 0.45\u20130.68; p<0.001). OS data showed a trend toward improvement (median OS: 34.7 vs. 28.3 months; HR=0.82, 95% CI: 0.67\u20131.01; p=0.06). The ORR was higher with abemaciclib (35.1% vs. 16.7%, p<0.001). Grade 3/4 adverse events were more frequent with abemaciclib (diarrhea: 12.5%; neutropenia: 24.8%) but manageable with dose adjustments.  \n\n**Conclusion:** Abemaciclib significantly improves PFS and ORR in HR+, HER2- advanced breast cancer, with a tolerable safety profile. These findings support its use as a standard-of-care option in this patient population.  \n\n**Clinical Trial Registration:** NCTXXXXXXX  \n\n**Keywords:** Abemaciclib, CDK4/6 inhibitor, hormone receptor-positive breast cancer, HER2-negative, progression-free survival\n\nAvailable PMIDs for Citation: 580237, 632330, 433862, 889006, 213266\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Abemaciclib. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Abemaciclib. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Abemaciclib will worsen Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Abemaciclib might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Abemaciclib) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Abemaciclib will worsen Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Abemaciclib **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Abemaciclib **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Abemaciclib is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Abemaciclib may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Abemaciclib **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/580237/",
                    "https://pubmed.ncbi.nlm.nih.gov/632330/",
                    "https://pubmed.ncbi.nlm.nih.gov/433862/",
                    "https://pubmed.ncbi.nlm.nih.gov/889006/",
                    "https://pubmed.ncbi.nlm.nih.gov/213266/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]